Marker Therapeutics Stock (NASDAQ:MRKR)


RevenueOwnershipFinancialsChart

Previous Close

$3.66

52W Range

$2.44 - $6.16

50D Avg

$3.21

200D Avg

$4.05

Market Cap

$31.41M

Avg Vol (3M)

$35.32K

Beta

1.54

Div Yield

-

MRKR Company Profile


Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Jul 16, 2002

Website

MRKR Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Related Party Service$3.50M--
Service$816.64K$5.50M-
Grant-$3.51M-
Grant income--$1.24M

Fiscal year ends in Dec 23 | Currency in USD

MRKR Financial Summary


Dec 23Dec 22Dec 21
Revenue$3.31M$9.00M$1.24M
Operating Income$-14.58M$-29.95M$-39.48M
Net Income$-16.97M$-29.92M$-41.87M
EBITDA$-14.58M$-26.27M$-36.32M
Basic EPS$-1.93$-3.58$-5.47
Diluted EPS$-1.93$-3.58$-5.47

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 21May 12, 21 | 9:24 PM
Q3 20Nov 10, 20 | 6:03 AM
Q1 20May 11, 20 | 9:43 PM

Peer Comparison


TickerCompany
PMVPPMV Pharmaceuticals, Inc.
IKNAIkena Oncology, Inc.
XCURExicure, Inc.
EWTXEdgewise Therapeutics, Inc.
ALECAlector, Inc.
AVTEAerovate Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
KROSKeros Therapeutics, Inc.
AGENAgenus Inc.
RNXTRenovoRx, Inc.
TPSTTempest Therapeutics, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
BNOXBionomics Limited
PTIXProtagenic Therapeutics, Inc.
CBIOGyre Therapeutics, Inc.
AADIAadi Bioscience, Inc.
LUMOLumos Pharma, Inc.